MCID: VRL017
MIFTS: 34

Viral Hemorrhagic Fever

Categories: Genetic diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Viral Hemorrhagic Fever

Summaries for Viral Hemorrhagic Fever

MalaCards based summary : Viral Hemorrhagic Fever, also known as hemorrhagic fevers, viral, is related to hemorrhagic fever and ebola hemorrhagic fever, and has symptoms including fever and pruritus. An important gene associated with Viral Hemorrhagic Fever is LBR (Lamin B Receptor). The drugs Ketotifen and Histamine have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and kidney, and related phenotypes are seizures and nausea and vomiting

Wikipedia : 76 Viral hemorrhagic fevers (VHFs) are a diverse group of animal and human illnesses in which fever and... more...

Related Diseases for Viral Hemorrhagic Fever

Diseases in the Hemorrhagic Fever family:

Viral Hemorrhagic Fever

Diseases related to Viral Hemorrhagic Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 17)
# Related Disease Score Top Affiliating Genes
1 hemorrhagic fever 11.6
2 ebola hemorrhagic fever 11.5
3 lassa fever 11.5
4 dengue disease 11.3
5 kyasanur forest disease 11.1
6 capillary leak syndrome 11.1
7 marburg hemorrhagic fever 11.1
8 omsk hemorrhagic fever 11.1
9 hantavirus pulmonary syndrome 10.1
10 viral infectious disease 10.1
11 hemorrhagic fever with renal syndrome 10.0
12 rift valley fever 10.0
13 coccidioidomycosis 10.0
14 dengue virus 9.8
15 thrombocytopenia 9.8
16 crimean-congo hemorrhagic fever 9.8
17 vascular disease 9.8

Graphical network of the top 20 diseases related to Viral Hemorrhagic Fever:



Diseases related to Viral Hemorrhagic Fever

Symptoms & Phenotypes for Viral Hemorrhagic Fever

Human phenotypes related to Viral Hemorrhagic Fever:

32 (show all 24)
# Description HPO Frequency HPO Source Accession
1 seizures 32 occasional (7.5%) HP:0001250
2 nausea and vomiting 32 frequent (33%) HP:0002017
3 encephalitis 32 occasional (7.5%) HP:0002383
4 hearing impairment 32 occasional (7.5%) HP:0000365
5 reduced consciousness/confusion 32 occasional (7.5%) HP:0004372
6 fever 32 hallmark (90%) HP:0001945
7 fatigue 32 hallmark (90%) HP:0012378
8 arthralgia 32 frequent (33%) HP:0002829
9 decreased liver function 32 frequent (33%) HP:0001410
10 abdominal pain 32 frequent (33%) HP:0002027
11 thrombocytopenia 32 frequent (33%) HP:0001873
12 migraine 32 frequent (33%) HP:0002076
13 myalgia 32 frequent (33%) HP:0003326
14 gastrointestinal hemorrhage 32 frequent (33%) HP:0002239
15 chest pain 32 frequent (33%) HP:0100749
16 diarrhea 32 frequent (33%) HP:0002014
17 epistaxis 32 frequent (33%) HP:0000421
18 skin rash 32 frequent (33%) HP:0000988
19 gingival bleeding 32 frequent (33%) HP:0000225
20 subcutaneous hemorrhage 32 frequent (33%) HP:0001933
21 spontaneous abortion 32 frequent (33%) HP:0005268
22 leukopenia 32 frequent (33%) HP:0001882
23 retrobulbar optic neuritis 32 occasional (7.5%) HP:0100654
24 recurrent bronchiolitis 32 occasional (7.5%) HP:0100501

UMLS symptoms related to Viral Hemorrhagic Fever:


fever, pruritus

Drugs & Therapeutics for Viral Hemorrhagic Fever

Drugs for Viral Hemorrhagic Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
2
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
3 tannic acid Approved Phase 4,Phase 1,Phase 2
4
Benzocaine Approved, Investigational Phase 4,Phase 1,Phase 2 94-09-7, 1994-09-7 2337
5 Anti-Allergic Agents Phase 4
6
Histamine Phosphate Phase 4 51-74-1 65513
7 Antipruritics Phase 4
8 Histamine H1 Antagonists Phase 4
9 Neurotransmitter Agents Phase 4
10 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1
11 Histamine Antagonists Phase 4
12 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Vasoconstrictor Agents Phase 4
15
Ivermectin Approved, Investigational, Vet_approved Phase 2, Phase 3 70288-86-7 6474909
16
Coal tar Approved Phase 2, Phase 3,Phase 1 8007-45-2
17
Loperamide Approved Phase 2, Phase 3 53179-11-6 3955
18
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 11103-57-4, 68-26-8 445354
19
Lactitol Investigational Phase 3 585-86-4 3871
20 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1,Not Applicable
21 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
22 Antiparasitic Agents Phase 2, Phase 3,Phase 1
23 DEET Phase 3
24 Insect Repellents Phase 3
25 Protective Agents Phase 3,Phase 1
26 Antibodies Phase 3,Phase 1,Phase 2,Not Applicable
27 Immunoglobulins Phase 3,Phase 1,Phase 2,Not Applicable
28 Antibodies, Blocking Phase 3
29 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
30 Krestin Phase 3,Phase 2,Phase 1
31 Vitamins Phase 3,Phase 2
32 Anti-Bacterial Agents Phase 2, Phase 3,Phase 1
33 Keratolytic Agents Phase 2, Phase 3,Phase 1
34 Iron-Dextran Complex Phase 3
35 Retinol palmitate Phase 3
36 Antioxidants Phase 3
37 Micronutrients Phase 3
38 retinol Phase 3
39 Trace Elements Phase 3
40
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
41
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
42
Ribavirin Approved Phase 2,Not Applicable 36791-04-5 37542
43
Angiotensin II Approved, Investigational Phase 1, Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
44
Irbesartan Approved, Investigational Phase 1, Phase 2 138402-11-6 3749
45
Azithromycin Approved Phase 1, Phase 2 83905-01-5 55185 447043
46
Sunitinib Approved, Investigational Phase 1, Phase 2 557795-19-4, 341031-54-7 5329102
47
chloroquine Approved, Investigational, Vet_approved Phase 1, Phase 2 54-05-7 2719
48
Lumefantrine Approved Phase 2 82186-77-4 6437380
49
Artemether Approved Phase 2 71963-77-4 119380 68911
50
Neomycin Approved, Vet_approved Phase 1, Phase 2,Phase 2 1404-04-2 8378

Interventional clinical trials:

(show top 50) (show all 270)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 High Frequency Ventilation During Off Pump Coronary Artery Bypass Graft (CABG) Completed NCT00863044 Phase 4
3 International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi Recruiting NCT03072030 Phase 4
4 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines Recruiting NCT03368495 Phase 4
5 Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals Recruiting NCT03132311 Phase 4
6 Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) Active, not recruiting NCT02991495 Phase 4
7 Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study) Active, not recruiting NCT02555072 Phase 4
8 Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old Not yet recruiting NCT03725618 Phase 4
9 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Unknown status NCT01374516 Phase 3
10 Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS) Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
11 Efficacy and Safety of Ivermectin Against Dengue Infection Unknown status NCT02045069 Phase 2, Phase 3 2 days Ivermectin;3 days Ivermectin;Placebo
12 Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR Unknown status NCT00938379 Phase 3 20% deet insect repellent;placebo control
13 STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola) Completed NCT02378753 Phase 2, Phase 3
14 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
15 Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS Completed NCT02360514 Phase 3 Hantavax injection
16 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed NCT01411241 Phase 3
17 Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea Completed NCT02342171 Phase 2, Phase 3
18 Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
19 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
20 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
21 Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012) Completed NCT02503202 Phase 3
22 Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine Completed NCT03161366 Phase 3
23 Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue Completed NCT03423173 Phase 3
24 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed NCT01466387 Phase 3
25 The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. Completed NCT01426243 Phase 3
26 Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Recruiting NCT02661464 Phase 3
27 Investigational Therapeutics for the Treatment of People With Ebola Virus Disease Recruiting NCT03719586 Phase 2, Phase 3 ZMapp;Remdesivir;MAb114;REGN-EB3
28 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults Recruiting NCT03342898 Phase 3
29 Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine Recruiting NCT02406729 Phase 3
30 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Active, not recruiting NCT02992418 Phase 3
31 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® Active, not recruiting NCT02993757 Phase 3
32 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Active, not recruiting NCT02979535 Phase 3
33 Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2 Active, not recruiting NCT02509494 Phase 3
34 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s) Active, not recruiting NCT03341637 Phase 3
35 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine Active, not recruiting NCT03525119 Phase 3
36 Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. Active, not recruiting NCT02699099 Phase 3
37 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults Not yet recruiting NCT03771963 Phase 3
38 Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola) Withdrawn NCT02307591 Phase 2, Phase 3 Best Supportive Care;Best Supportive Care + Amiodarone
39 Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms Unknown status NCT01973855 Phase 2 Western Medicine;TCM and Western Medicine
40 Treatment of Japanese Encephalitis Unknown status NCT00216268 Phase 2 Ribavirin
41 Multiple Treatments for Ebola Virus Disease (EVD) Unknown status NCT02380625 Phase 1, Phase 2 Azithromycin;Sunitinib and Erlotinib;Atorvastatin and Irbesartan
42 The Effect of Chloroquine in the Treatment of Patients With Dengue Unknown status NCT00849602 Phase 1, Phase 2 Placebo;Chloroquine
43 Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever Completed NCT01601613 Phase 2 activated recombinant human factor VII;placebo
44 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed NCT01187433 Phase 2
45 A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
46 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
47 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Completed NCT01550289 Phase 2
48 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Completed NCT00740155 Phase 2
49 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
50 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed NCT00993447 Phase 2

Search NIH Clinical Center for Viral Hemorrhagic Fever

Genetic Tests for Viral Hemorrhagic Fever

Anatomical Context for Viral Hemorrhagic Fever

MalaCards organs/tissues related to Viral Hemorrhagic Fever:

41
Liver, Skin, Kidney, Testes, T Cells

Publications for Viral Hemorrhagic Fever

Articles related to Viral Hemorrhagic Fever:

(show top 50) (show all 66)
# Title Authors Year
1
Aeromedical Transfer of Patients with Viral Hemorrhagic Fever. ( 30431424 )
2019
2
Murine Models for Viral Hemorrhagic Fever. ( 28986841 )
2018
3
A Primate Model for Viral Hemorrhagic Fever. ( 28986843 )
2018
4
Development of Mobile Laboratory for Viral Hemorrhagic Fever Detection in Africa. ( 29917112 )
2018
5
Tangeretin, an extract from Citrus peels, blocks cellular entry of arenaviruses that cause viral hemorrhagic fever. ( 30339847 )
2018
6
Development and preliminary evaluation of a multiplexed amplification and next generation sequencing method for viral hemorrhagic fever diagnostics. ( 29155823 )
2017
7
Disposable cartridge platform for rapid detection of viral hemorrhagic fever viruses. ( 28194457 )
2017
8
Viral hemorrhagic fever in the tropics: Report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine. ( 29128377 )
2017
9
Molecular pathogenesis of viral hemorrhagic fever. ( 28555386 )
2017
10
Exploring the Immunopathogenesis of Viral Hemorrhagic Fever in Mice with a Humanized Immune System. ( 29018450 )
2017
11
Systems Pharmacology Uncovers the Multiple Mechanisms of Xijiao Dihuang Decoction for the Treatment of Viral Hemorrhagic Fever. ( 27239215 )
2016
12
Hospital Preparations for Viral Hemorrhagic Fever Patients and Experience Gained from Admission of an Ebola Patient. ( 26812146 )
2016
13
The Epi Info Viral Hemorrhagic Fever (VHF) Application: A Resource for Outbreak Data Management and Contact Tracing in the 2014-2016 West Africa Ebola Epidemic. ( 27587635 )
2016
14
Lujo viral hemorrhagic fever: considering diagnostic capacity and preparedness in the wake of recent Ebola and Zika virus outbreaks. ( 27593704 )
2016
15
Viral Hemorrhagic Fever Diagnostics. ( 26354968 )
2015
16
Addressing the Complications of Ebola and Other Viral Hemorrhagic Fever Infections: Using Insights from Bacterial and Fungal Sepsis. ( 26425845 )
2015
17
Animal models for some important RNA viruses of public health concern in SEARO countries: Viral hemorrhagic fever. ( 25815861 )
2015
18
Does Viral Hemorrhagic Fever Represent Reactive Hemophagocytic Syndrome? ( 26136549 )
2015
19
A Multiplex PCR/LDR Assay for the Simultaneous Identification of Category A Infectious Pathogens: Agents of Viral Hemorrhagic Fever and Variola Virus. ( 26381398 )
2015
20
Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. ( 26186980 )
2015
21
Diagnostic schemes for reducing epidemic size of African viral hemorrhagic fever outbreaks. ( 25212079 )
2014
22
Simultaneous detection of IgG antibodies associated with viral hemorrhagic fever by a multiplexed Luminex-based immunoassay. ( 24631566 )
2014
23
The pathogenesis of severe Fever with thrombocytopenia syndrome virus infection in alpha/beta interferon knockout mice: insights into the pathologic mechanisms of a new viral hemorrhagic Fever. ( 24257618 )
2014
24
Animal Models for Viral Hemorrhagic Fever. ( 24690109 )
2014
25
Animal models of viral hemorrhagic fever. ( 25448088 )
2014
26
Viral hemorrhagic fever cases in the country of Georgia: Acute Febrile Illness Surveillance Study results. ( 24891463 )
2014
27
Genomic analysis of filoviruses associated with four viral hemorrhagic fever outbreaks in Uganda and the Democratic Republic of the Congo in 2012. ( 23711383 )
2013
28
Viral hemorrhagic fever viruses. ( 24314803 )
2013
29
Outbreak of viral hemorrhagic fever caused by dengue virus type 3 in Al-Mukalla, Yemen. ( 23497142 )
2013
30
Alkhurma viral hemorrhagic fever virus: proposed guidelines for detection, prevention, and control in Saudi Arabia. ( 22860139 )
2012
31
Simian hemorrhagic fever virus infection of rhesus macaques as a model of viral hemorrhagic fever: clinical characterization and risk factors for severe disease. ( 22014505 )
2011
32
Lessons learned during active epidemiological surveillance of Ebola and Marburg viral hemorrhagic fever epidemics in Africa. ( 21413569 )
2010
33
Aerosol exposure to the angola strain of marburg virus causes lethal viral hemorrhagic Fever in cynomolgus macaques. ( 20807825 )
2010
34
Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. ( 20846417 )
2010
35
Reappearance of viral hemorrhagic fever with renal syndrome in northwestern Greece. ( 19926507 )
2010
36
Gene expression in primate liver during viral hemorrhagic fever. ( 19216742 )
2009
37
Viral hemorrhagic fever-induced acute kidney injury. ( 18620963 )
2008
38
MassTag polymerase chain reaction for differential diagnosis of viral hemorrhagic fever. ( 16704825 )
2006
39
Viral hemorrhagic fever - an ICU perspective. ( 16827967 )
2006
40
Alkhumra virus infection, a new viral hemorrhagic fever in Saudi Arabia. ( 16038757 )
2005
41
Pathogenesis of viral hemorrhagic fever. ( 15955687 )
2005
42
Role of specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome. ( 14978138 )
2004
43
Correction: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. ( 15171793 )
2004
44
Emerging roles of tissue factor in viral hemorrhagic fever. ( 15324737 )
2004
45
Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. ( 14720304 )
2004
46
Implementation of the Canadian contingency plan for a case of suspected viral hemorrhagic fever. ( 12725358 )
2003
47
Viral hemorrhagic fever--a vascular disease? ( 12783108 )
2003
48
Treating viral hemorrhagic fever. ( 14600838 )
2003
49
Mitogen therapy for biological warfare/terrorist attacks and viral hemorrhagic fever control. ( 11915170 )
2002
50
Viral hemorrhagic fever in Pakistan: awareness among health care personnel. ( 12174494 )
2002

Variations for Viral Hemorrhagic Fever

Expression for Viral Hemorrhagic Fever

Search GEO for disease gene expression data for Viral Hemorrhagic Fever.

Pathways for Viral Hemorrhagic Fever

GO Terms for Viral Hemorrhagic Fever

Sources for Viral Hemorrhagic Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....